0
0
New Delhi, May 9, 2025 – In a landmark breakthrough poised to reshape diabetes diagnosis and treatment, researchers from the Madras Diabetes Research Foundation (MDRF), Chennai, and Washington University School of Medicine, St. Louis, have identified a previously unknown genetic subtype of Maturity-Onset Diabetes of the Young (MODY). The findings, published ahead of print in the journal Diabetes, reveal a novel disease mechanism involving the ABCC8 gene, which is crucial for insulin production in the pancreas.
A New Mechanism in MODY: Loss of Function in ABCC8
Traditionally, mutations in the ABCC8 gene linked to diabetes have been “Gain of Function” (GOF) mutations, which increase the activity of the protein and are associated with neonatal diabetes or ABCC8 MODY (also known as MODY 12) in adults. However, the new research identified “Loss of Function” (LOF) mutations in Indian patients. These LOF mutations reduce or abolish the protein’s activity, typically causing persistent low blood sugar (hypoglycemia) in childhood-a condition known as Congenital Hyperinsulinism (CHI).
Remarkably, the study found that some individuals who experienced CHI in childhood later developed high blood sugar (diabetes) as adults. This is the first time such a transition has been demonstrated in a MODY subtype, highlighting a unique disease pathway.
“This is the first demonstration of this mechanism in a MODY subtype to our knowledge,” said Prof. Colin G. Nichols, lead researcher from Washington University School of Medicine.
Implications for Diagnosis and Treatment
The discovery was led in India by Dr. Radha Venkatesan, Executive Scientific Officer and Head of Molecular Genetics at MDRF. She described the finding as a “significant advancement in understanding the functional dynamics of potassium ATP (K-ATP) channels in pancreatic beta cells,” which are central to insulin release.
Unlike other MODY subtypes-such as MODY 1, MODY 3, and MODY 12-which generally respond well to sulphonylurea medications, patients with this new subtype do not benefit from these drugs. This underscores the need for personalized treatment strategies and highlights the importance of genetic testing for accurate diagnosis.
“By identifying these distinct subtypes of MODY, we are paving the way for tailored therapies and improved outcomes for patients who would otherwise be misdiagnosed or inadequately treated,” said Dr. V. Mohan, Chairman of MDRF.
Broader Impact and Future Directions
MODY is a rare, inherited form of diabetes caused by mutations in a single gene and typically manifests in adolescence or early adulthood. Thirteen MODY subtypes have been recognized so far, but this newly identified variant challenges established views on disease development and progression.
The researchers emphasize that their findings could lead to the development of new diabetes drugs targeting this specific genetic pathway. They also call for broader access to genetic screening, especially in low- and middle-income countries where such diagnostics are often unavailable.
Expert Perspectives
-
Prof. Colin G. Nichols (Washington University): Highlighted the novel mechanism and the importance of functional studies alongside genetic testing.
-
Dr. Radha Venkatesan (MDRF): Stressed the need for recognizing K-ATP channel mutations as distinct disease subtypes with different clinical implications.
-
Dr. V. Mohan (MDRF): Called the discovery a major milestone for precision medicine in diabetes care.
What is MODY?
MODY is an uncommon, inherited form of diabetes caused by single-gene mutations that impair insulin production. Unlike type 1 or type 2 diabetes, MODY often presents in younger individuals and requires genetic testing for accurate diagnosis. Treatment varies by subtype, making precise identification critical for effective management.
Disclaimer:
This article is based on recent scientific findings published in the journal Diabetes and statements from leading researchers. The information is intended for general awareness and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Individuals concerned about diabetes or genetic conditions should consult qualified healthcare professionals for personalized guidance.
Citations:
